252953-86-9 Usage
Uses
Used in Pharmaceutical Industry:
(Z)-1-(2,4-dichlorophenyl)-3-(diMethylaMino)-2-(4-Methyl-1H-iMidazol-2-yl)prop-2-en-1-one is used as a compound in the pharmaceutical industry for its potential role in the development of new drugs. Its unique structure and functional groups may contribute to the creation of novel therapeutic agents.
Used in Chemical Synthesis:
In the field of chemical synthesis, (Z)-1-(2,4-dichlorophenyl)-3-(diMethylaMino)-2-(4-Methyl-1H-iMidazol-2-yl)prop-2-en-1-one is used as a building block or intermediate for the synthesis of more complex molecules. Its versatile structure allows for further functionalization and modification to create a wide range of compounds with different properties and applications.
Used as a Ligand in Metal-Catalyzed Reactions:
(Z)-1-(2,4-dichlorophenyl)-3-(diMethylaMino)-2-(4-Methyl-1H-iMidazol-2-yl)prop-2-en-1-one is also used as a ligand in metal-catalyzed reactions. Its ability to coordinate with metal centers can enhance the efficiency and selectivity of various chemical transformations, making it a valuable tool in organic chemistry and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 252953-86-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,9,5 and 3 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 252953-86:
(8*2)+(7*5)+(6*2)+(5*9)+(4*5)+(3*3)+(2*8)+(1*6)=159
159 % 10 = 9
So 252953-86-9 is a valid CAS Registry Number.
252953-86-9Relevant academic research and scientific papers
GSK-3 inhibitors
-
Page/Page column 19, (2008/06/13)
This invention relates to methods of treating or preventing bone loss by administering to a human or animal subject pyrimidine and pyridine derivatives that inhibit the activity of glycogen synthase kinase 3 (GSK3), to pharmaceutical compositions containi
Inhibitors of glycogen synthase kinase 3
-
, (2008/06/13)
New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
